Nuclear Is Back in a Big Way. Here Are 2 Stocks to Consider.

The article highlights a growing but still relatively small global nuclear energy market, with estimates ranging from $41.6 billion in 2026 to $52.6 billion by 2034. BWX Technologies reported 2025 revenue of $3.2 billion and guided to $3.7 billion in 2026, while Cameco posted 2025 revenue of $3.4 billion and gross profit of $970 million. BWX also announced an acquisition of Precision Components Group to expand U.S. nuclear production capacity, but the piece is largely an investment overview rather than a market-moving event.

Analysis

The important read-through is that nuclear is becoming a policy-and-procurement story before it is a volume story. That favors the small set of suppliers with licensed capacity, heavy fabrication expertise, and regulatory moats; the constraint is not demand, it is how fast the industrial base can actually deliver. BWXT sits closer to the bottleneck than most investors appreciate, so incremental contract wins and tuck-in M&A can translate into outsized pricing power even if sector-wide market growth remains only mid-single digits.

CCJ’s setup is different: it is less about near-term volume and more about security-of-supply optionality. The market is assigning uranium a scarcity premium, but that premium is vulnerable if utilities delay restocking or if higher prices unlock marginal supply faster than expected. The big second-order effect is that higher confidence in fuel availability can improve the willingness of reactors, governments, and data-center operators to commit capital to new build or life-extension projects, which would help BWXT more than CCJ over a 12-24 month horizon.

The valuation gap matters because both names are being treated as quality growth, but their catalysts have different durability. BWXT’s multiple can stay elevated if the acquisition integrates cleanly and U.S. capacity expands on schedule; if integration slips, the stock is likely to de-rate quickly because the market is paying for execution already. CCJ is more exposed to a commodity-style reversal: if uranium spot cools, the equity can underperform even while fundamentals remain healthy, because expectations are stretched and the dividend is too small to cushion downside.

Consensus is probably underweighting the lag between headline enthusiasm and actual earnings power. Nuclear supply chains have long lead times, so the real upside is not in the next quarter but in a multi-year rerating of industrial suppliers that can credibly scale inside a constrained regulatory framework. The risk is that investors extrapolate the theme too aggressively before utilities, governments, and private buyers convert rhetoric into signed orders.

Key Decisions for Investors

• Long BWXT on a 6-12 month horizon on pullbacks, targeting execution-driven upside from capacity expansion and M&A; risk/reward is attractive as long as management proves it can convert backlog into margin rather than just revenue.
• Use CCJ as a tactical momentum long only if uranium prices confirm higher lows; otherwise avoid chasing the multiple, since the stock is priced for continued scarcity and has limited dividend support.
• Pair trade: long BWXT / short a broad industrials ETF over 3-9 months to isolate nuclear infrastructure upside from cyclical manufacturing beta; the trade works if nuclear capex rerates faster than the macro cycle slows.
• For more risk-tolerant accounts, buy BWXT call spreads 6-9 months out into any post-deal weakness; this expresses upside from execution while limiting multiple-compression risk.
• If uranium spot rolls over or utility contracting slows, trim CCJ first and rotate toward BWXT, which has more idiosyncratic earnings visibility and less direct commodity exposure.